Cargando…
Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study
Levamisole was initially prescribed for the treatment of intestinal worms. Because of immunomodulatory properties, levamisole has been used in inflammatory pathologies and in cancers in association with 5‐fluorouracil. Levamisole is misused as a cocaine adulterant. Post‐marketing reports have implic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293185/ https://www.ncbi.nlm.nih.gov/pubmed/34390273 http://dx.doi.org/10.1111/bcp.15037 |
_version_ | 1784749559789912064 |
---|---|
author | Campillo, Jérémy T. Eiden, Céline Boussinesq, Michel Pion, Sébastien D. S. Faillie, Jean‐Luc Chesnais, Cédric B. |
author_facet | Campillo, Jérémy T. Eiden, Céline Boussinesq, Michel Pion, Sébastien D. S. Faillie, Jean‐Luc Chesnais, Cédric B. |
author_sort | Campillo, Jérémy T. |
collection | PubMed |
description | Levamisole was initially prescribed for the treatment of intestinal worms. Because of immunomodulatory properties, levamisole has been used in inflammatory pathologies and in cancers in association with 5‐fluorouracil. Levamisole is misused as a cocaine adulterant. Post‐marketing reports have implicated levamisole in the occurrence of adverse drug reactions (ADRs) and its use is now limited in Europe and North America. In contrast, all other parts of the World continue to use single‐dose levamisole as an anthelmintic. The aim of this study was to identify ADRs reported after levamisole exposure in VigiBase, the World Health Organisation's pharmacovigilance database, and analyse their frequency compared to other drugs and according to levamisole type of use. METHODS: All levamisole‐related ADRs were extracted from VigiBase. Disproportionality analyses were conducted to investigate psychiatric, hepatobiliary, renal, vascular, nervous, blood, skin, cardiac, musculoskeletal and general ADRs associated with levamisole and other drugs exposure. In secondary analyses, we compared the frequency of ADRs between levamisole and mebendazole and between levamisole type of use. RESULTS: Among the 1763 levamisole‐related ADRs identified, psychiatric disorders (reporting odds ratio with 95% confidence intervals: 1.4 [1.2–2.6]), hepatobiliary disorders (2.4 [1.9–4.3]), vasculitis (6.5 [4.1–10.6]), encephalopathy (22.5 [17.4–39.9]), neuropathy (4.3 [2.9–7.1]), haematological disorders, mild rashes and musculoskeletal disorders were more frequently reported with levamisole than with other drug. The majority of levamisole‐related ADRs occurred when the drug was administrated for a non–anti‐infectious indication. CONCLUSION: The great majority of the levamisole‐related ADRs concerned its immunomodulatory indication and multiple‐dose regimen. Our results suggest that single‐dose treatments for anthelmintic action have a good safety profile. |
format | Online Article Text |
id | pubmed-9293185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92931852022-07-20 Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study Campillo, Jérémy T. Eiden, Céline Boussinesq, Michel Pion, Sébastien D. S. Faillie, Jean‐Luc Chesnais, Cédric B. Br J Clin Pharmacol Original Articles Levamisole was initially prescribed for the treatment of intestinal worms. Because of immunomodulatory properties, levamisole has been used in inflammatory pathologies and in cancers in association with 5‐fluorouracil. Levamisole is misused as a cocaine adulterant. Post‐marketing reports have implicated levamisole in the occurrence of adverse drug reactions (ADRs) and its use is now limited in Europe and North America. In contrast, all other parts of the World continue to use single‐dose levamisole as an anthelmintic. The aim of this study was to identify ADRs reported after levamisole exposure in VigiBase, the World Health Organisation's pharmacovigilance database, and analyse their frequency compared to other drugs and according to levamisole type of use. METHODS: All levamisole‐related ADRs were extracted from VigiBase. Disproportionality analyses were conducted to investigate psychiatric, hepatobiliary, renal, vascular, nervous, blood, skin, cardiac, musculoskeletal and general ADRs associated with levamisole and other drugs exposure. In secondary analyses, we compared the frequency of ADRs between levamisole and mebendazole and between levamisole type of use. RESULTS: Among the 1763 levamisole‐related ADRs identified, psychiatric disorders (reporting odds ratio with 95% confidence intervals: 1.4 [1.2–2.6]), hepatobiliary disorders (2.4 [1.9–4.3]), vasculitis (6.5 [4.1–10.6]), encephalopathy (22.5 [17.4–39.9]), neuropathy (4.3 [2.9–7.1]), haematological disorders, mild rashes and musculoskeletal disorders were more frequently reported with levamisole than with other drug. The majority of levamisole‐related ADRs occurred when the drug was administrated for a non–anti‐infectious indication. CONCLUSION: The great majority of the levamisole‐related ADRs concerned its immunomodulatory indication and multiple‐dose regimen. Our results suggest that single‐dose treatments for anthelmintic action have a good safety profile. John Wiley and Sons Inc. 2021-09-15 2022-03 /pmc/articles/PMC9293185/ /pubmed/34390273 http://dx.doi.org/10.1111/bcp.15037 Text en © 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Campillo, Jérémy T. Eiden, Céline Boussinesq, Michel Pion, Sébastien D. S. Faillie, Jean‐Luc Chesnais, Cédric B. Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study |
title | Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study |
title_full | Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study |
title_fullStr | Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study |
title_full_unstemmed | Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study |
title_short | Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study |
title_sort | adverse reactions with levamisole vary according to its indications and misuse: a systematic pharmacovigilance study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293185/ https://www.ncbi.nlm.nih.gov/pubmed/34390273 http://dx.doi.org/10.1111/bcp.15037 |
work_keys_str_mv | AT campillojeremyt adversereactionswithlevamisolevaryaccordingtoitsindicationsandmisuseasystematicpharmacovigilancestudy AT eidenceline adversereactionswithlevamisolevaryaccordingtoitsindicationsandmisuseasystematicpharmacovigilancestudy AT boussinesqmichel adversereactionswithlevamisolevaryaccordingtoitsindicationsandmisuseasystematicpharmacovigilancestudy AT pionsebastiends adversereactionswithlevamisolevaryaccordingtoitsindicationsandmisuseasystematicpharmacovigilancestudy AT failliejeanluc adversereactionswithlevamisolevaryaccordingtoitsindicationsandmisuseasystematicpharmacovigilancestudy AT chesnaiscedricb adversereactionswithlevamisolevaryaccordingtoitsindicationsandmisuseasystematicpharmacovigilancestudy |